Fubotv earnings beat by $0.10, revenue topped estimates
Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary at Twist Bioscience Corp (NASDAQ:TWST), sold 785 shares of common stock on August 4, 2025, at a price of $28.364, for a total value of $22265. Following the transaction, Cho directly owns 103827 shares of Twist Bioscience Corp, worth approximately $2.7 million at current market prices. The company maintains a strong liquidity position with a current ratio of 3.9, indicating robust short-term financial health. For deeper insights into TWST’s valuation and 11 additional key investment tips, check out the comprehensive analysis available on InvestingPro.
In other recent news, Twist Bioscience reported an 18% year-over-year increase in revenue for Q3 2025, reaching $96.1 million. Despite the revenue growth, the company recorded an adjusted EBITDA loss of $8 million, though this marks an improvement compared to the previous fiscal year. In other developments, JPMorgan has lowered its price target for Twist Bioscience from $33 to $25, maintaining an Underweight rating. TD Cowen also adjusted its price target from $58 to $36, while keeping a Buy rating, citing revised fiscal year 2025 guidance due to a key customer’s transition affecting Next-Generation Sequencing revenue. Evercore ISI reduced its price target from $50 to $46, maintaining an Outperform rating, acknowledging strong performance in the next-generation sequencing segment and solid gross margin results. Additionally, Twist Bioscience announced the appointment of Trynka Shineman Blake to its board of directors, where she will serve on the audit committee.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.